PAGE 43 --- Literally on page 43 of the 98 page document it states:
The Company signed a non-binding term sheet in August 2018 with a global pharmaceutical company for the licensing/rights to Brilacidin for treating oral mucositis and inflammatory bowel diseases. Initial payments, milestone payments and royalties are being negotiated in accordance with the non-binding term sheet. The pharmaceutical company is now engaged in further due diligence. Management can offer no assurances that the parties will enter into a binding definitive agreement.
I don't think this is LEO TOUTING :)
Maybe he says it again in the next 10K...you'll never know if you don't stick around! I assume you will be here to find out :)
Minutes are going to be provided in the next week or two and those will be presented to some of the partners that are negotiating and lets see what happens. B-OM - HUGE MARKET -- UNTAPPED. Someone will want in, and I think it will be for all of B indications ONLY if they give a HUGE upfront. There is good money to be made of B franchise...who will step up and reserve the right to call it theirs! stick around.